Dear Colleagues,

In recent years, type 2 diabetes therapy has undergone numerous developments, both due to the introduction of new antihyperglycemic therapies, particularly Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists, and due to the deepening of pathophysiological and patients’ cardiovascular prognosis knowledge. Physicians then has moving from a “glucocentric” view, with the main objective of reducing glycosylated hemoglobin in patients not well targeted, to a more global vision of the patient, aimed at treating also other cardiovascular risk factors as well.

More specifically, lifestyle modifications (smoking and sedentary lifestyle), targeted blood pressure and LDL cholesterol levels are today recognized as complementary and indispensable objectives for an adequate diabetes therapy, both in type 1 and in type 2 diabetes patients. Recent evidence has in fact shown that the improvement of cardiovascular outcomes is closely linked to the modification of all these risk factors, and that the correction of HbA1c alone does not allow to achieve the goal.

In this issue, entitled “Cardiovascular Risk Factors and Disease Management in Type 2 Diabetic Patients” we present recent advances in the field of Diabetes therapy and its management to modify risk factor levels and patients’ CV outcome.

Prof. Ferdinando Carlo Sasso and Dr. Raffaele Galiero

Guest Editors